NeuroSense Therapeutics Ltd. Dec 2024 Form 6-K: Financial Update & Future Filings

Here are the key insights extracted from the provided section of the financial report:

1. Report Type and Filing Information:

• This is a Form 6-K, which is a report of a foreign private issuer.
• It was filed with the Securities and Exchange Commission (SEC) and is governed under the Securities Exchange Act of 1934.

2. Company Information:

• Company Name: NeuroSense Therapeutics Ltd.
• Address: 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
• Contact: +972-9-799-6183.

3. Reporting Period:

• The report covers the month of December 2024.

4. Annual Report Filing Status:

• The company has indicated that it will file annual reports under Form 20-F.

5. Recent Developments:

• On December 18, 2024, NeuroSense Therapeutics Ltd. issued a press release titled "NeuroSense Management Provides Business Update and Third Quarter 2024 Financial Results."
• This press release is included as Exhibit 99.1 in the report.

6. Incorporation by Reference:

• The Q3 2024 financial results and other relevant information from the press release attached as Exhibit 99.1 are incorporated by reference into the company's registration statements on Form F-3 and Form S-8.

7. Signature and Authorization:

• The report is signed by Alon Ben-Noon, indicating that the necessary authorization has been obtained.

Overall, this report serves as a formal update from NeuroSense Therapeutics Ltd., including their recent financial performance and future filing commitments, which are crucial for investors and stakeholders keeping track of the company's activities.